Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
The DOI matches its Crossref record.
Abstract
LBA4011 Background: Cetuximab, a chimaeric monoclonal antibody against the epidermal growth factor receptor (EGFR) has shown efficacy in patients (pts) with ACC. Preclinical and early clinical studies suggest a benefit for combining VEGF and EGFR targeting agents in ACC. The CAIRO2 study was designed to investigate the effect of adding cetuximab to capecitabine and oxaliplatin (CapOx) and bevacizumab in ACC. Methods: Previously untreated pts were randomized between capecitabine 1000 mg/m² orally b.i.d. day 1–14, oxaliplatin 130 mg/m² i.v. day 1, and bevacizumab 7.5 mg/kg i.v. day 1 (arm A) or the same schedule plus cetuximab 400 mg/m² i.v. in week 1, cycle 1, and 250 mg/m² i.v. weekly thereafter (arm B). All cycles were given q 3 weeks. The primary endpoint was progression-free survival (PFS). Response was assessed q 3 cycles (RECIST). The study was designed to detect an increase in the median PFS of 3 months from 11 to 14 months (21% reduction in the hazard ratio of progression, HR=0.79) Results: A total of 755 patients, WHO PS 0–1 and median age 62 yrs (range 27–83), were randomized between June 2005 and December 2006. Of 736 eligible pts, 730 patients started protocol treatment with a median number of cycles of 10 (range 1–39) in arm A and 9 (range 1–40) in arm B. At the time of this analysis, median follow-up is 14.7 months (range 4–28 months) with 140 patients (19%) still receiving treatment. Reasons for end of treatment did not differ between treatment arms, and 28% of pts in arm A and 30% of pts in arm B discontinued treatment for reasons of toxicity. Grade 3–4 toxicity occurred in 71.8% (arm A) and 81.9% (arm B, p=0.0012). Excluding cetuximab-related skin toxicity resulted in similar rates: 71.8% (arm A) and 74.5% (arm B, p=0.40). Most frequent grade 3–4 toxicities in arm A vs B were diarrhea (19.2 vs 25.8%), fatigue (12.6% vs 15.3%), hypertension (13.7% vs 8.8%), nausea (8.5 vs 6.3%), sensory neuropathy (9.6% vs 7.9%), acneiform rash (0.5% vs 25.2%) and hand-foot skin reaction (18.4% vs 18.1%). A total of 554 progressions or deaths were observed: 264 in arm A and 290 in arm B. Median PFS was 10.7 months (CI: 9.7;12.5) in arm A and 9.8 months (CI: 8.6;10.7) in arm B (p=0.019, HR 1.22 (1.03;1.44). Response rates (PR + CR) were 40.6% (CI: 34.5;46.9) vs 43.9% (CI: 37.8;50.1, p=0.44 ), median OS 20.4 (CI: 18.1;26.1) months vs 20.3 months (CI: 17.9;21.6, p=0.21), and 60-day mortality 1.9% vs 2.4%. Conclusions: The combination of both antibodies, cetuximab and bevacizumab, to CapOx results in a significant decrease in PFS compared to bevacizumab and CapOx. Besides skin toxicity, cetuximab did not add additional toxicity to CapOx and bevacizumab. Updated results will be presented at the meeting, including data on KRAS in relation to outcome of treatment. No significant financial relationships to disclose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
“The review of the evidence on which this PCO is based consists primarily of the rigorous systematic review of the literature conducted by the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC).(1-10) Details of the BCBSA TEC assessment can be found in the full TEC report, which is availa…”
MethodInfluentialHecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Metadata
- Authors
- Punt, C. J., Tol, J., Rodenburg, C. J., Cats, A., Creemers, G., Schrama, J. G., Erdkamp, F. L., Vos, A., Mol, L., & Antonini, N. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-20
- Volume
- 26
- Issue
- 15_suppl
- Pages
- LBA4011-LBA4011
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1782669727
- Cited by
- 128
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). https://app.cochat.ai/papers/10.1200/jco.2008.26.15_suppl.lba4011
- The paper
- Punt, C. J., Tol, J., Rodenburg, C. J., Cats, A., Creemers, G., Schrama, J. G., Erdkamp, F. L., Vos, A., Mol, L., & Antonini, N. F. (2008). Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.26.15_suppl.lba4011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.